CDSCO Approval for First GLP-1 Therapy for Fatty Liver Disease
Why It Matters
The rise of metabolic diseases like MASH and obesity is a major public health challenge in India. Understanding new medical technologies (like GLP-1 therapies) and the role of regulatory bodies (CDSCO) is essential for answering questions on health, biotechnology, and the management of non-communicable diseases in GS2 and GS3.



